inspirator schreef op 26 juli 2016 23:30:
However, colon cancer is the second-leading cause of cancer death in the U.S., and 134?000 people are diagnosed with it every year. When caught early, it's far easier to treat, a fact that highlights the need for people to get screened for the disease, and the huge potential for Cologuard.
Management pegs Cologuard's addressable opportunity at $4 billion, and thinks the company will complete 240,000 screenings and deliver at least $90 million in sales this year. Those numbers suggest aggressive investors might want to consider buying Exact Sciences shares, especially if they retreat in the coming weeks.
MDXH's royalty stream from Cologuard is worth more than its market capitalization.
Op basis van verkopen Cologuard gaat koers MdxHealth morgen ook met 28% stijgen. De 50.000 op 3,60 in de laat zijn verdwenen bij de opening vd beurs.
SelectMdx, AssureMdx, ConfurmMdx en PredictMdx gaan de koers van MdxHealth pas echt stuwen naar 15,25 cq 47 euro.